Clinical Trial Search

Primary: The Investigators Will Assess Effect Size With Each Scale for Detecting Change From Baseline and Change Between Amantadine and Placebo; Allowing Assessment of…

Primary: Overall Complete Response Rate — 10; 10 percentage of participants

Primary: Number of Micturations Per 24 Hour Period — 8.78; 9.19; 8.00; 8.94 Number of micturations per 24 hours — p=0.53

Primary: Baseline Mean Pain Score — 5.93; 6.08 units on a scale

Primary: Rate of 7-day Point Prevalence Abstinence at the End of the Relapse Prevention Phase (Study Week 53) in the Extended Duration Pharmacotherapy Group vs. the Placebo Group…

Primary: Change From Baseline in WOMAC A1 Subscore at Week 26 — -28.0 units on a scale — p=<0.0001

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 — -1.52; -1.69 percentage of glycosylated hemoglobin

Primary: Time to Onset of Near-syncopal Symptoms During Tilt Table Testing — 551.3; 461.0 seconds — p=0.1460

Primary: Percentage of Participants With a Preference for Autoinjector A Versus Autoinjector B — 41.7; 43.5; 36.8 percentage of participants

Primary: Change in Blood Pressure From Baseline to Treatment — -7.56; -7.97; -7.68; -11.70 mmHg — p=<0.0001

Primary: To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4…

Primary: Safety and Tolerability of Zipsor® in Pediatric Subjects, Ages 12 to 17 Years — 12; 0; 1; 1 participants

Primary: Muscle Function — 1.14; 1.50 kilograms

Primary: The Magnitude of the Early Asthmatic Response, Expressed as a Percentage Change in FEV1. — -30.5; -39.0; -31.9 percentage fall FEV1

Primary: Mean Diurnal Intraocular Pressure (IOP) at Week 6 — 17.44; 20.34 mmHg